Skip to main content
Clinical Trials/NCT00471523
NCT00471523
Completed
Phase 4

Clomiphene Citrate Versus Metformin as First-Line Approach for the Treatment of Anovulation in Infertile Patients With Polycystic Ovary Syndrome

University Magna Graecia1 site in 1 country80 target enrollmentMay 2006

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Infertility
Sponsor
University Magna Graecia
Enrollment
80
Locations
1
Primary Endpoint
Pregnancy rate
Status
Completed
Last Updated
18 years ago

Overview

Brief Summary

Clomiphene citrate (CC) and metformin are two effective drugs used to induce ovulation in patients with polycystic ovary syndrome (PCOS), even if it is still unclear which compound between them should be initially administered. The aim of the study will be to compare in a clinical setting the efficacy of CC and metformin as first-line approaches for treating anovulation in infertile PCOS patients.

Detailed Description

Eighty infertile anovulatory patients with PCOS will be allocated in two body mass index (BMI)- and age-matched groups (experimental and control groups). Forty patients will receive the experimental treatment consisting of six months of 1700 mg/day metformin administration (experimental group), whereas other forty patients will receive CC administered using a traditional incremental-doses protocol (control group). In both groups, patients who will ovulate under treatment will continue the therapy for a total of six months. During the study, the clinical and reproductive outcomes, and the adverse experience will be evaluated in each patient.

Registry
clinicaltrials.gov
Start Date
May 2006
End Date
March 2007
Last Updated
18 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
University Magna Graecia

Eligibility Criteria

Inclusion Criteria

  • Anovulatory infertility related to polycystic ovary syndrome

Exclusion Criteria

  • Neoplastic, metabolic, hepatic, and cardiovascular disorders or other concurrent medical illnesses
  • Hypothyroidism, hyperprolactinemia, Cushing's syndrome, and non-classical congenital adrenal hyperplasia
  • Current or previous (within the last six months) use of oral contraceptives, glucocorticoids, antiandrogens, ovulation induction agents, antidiabetic and anti-obesity drugs or other hormonal drugs.
  • Organic pelvic diseases
  • Previous pelvic surgery
  • Suspected peritoneal factor infertility
  • Tubal or male factor infertility or sub-fertility

Outcomes

Primary Outcomes

Pregnancy rate

Time Frame: 10 months

Secondary Outcomes

  • Abortion rate(10 months)
  • Time to first pregnancy(10 months)
  • Adverse events(10 months)
  • Ovulation rate(6 months)
  • N. pregnancies/n. ovulatory cycles(10 months)

Study Sites (1)

Loading locations...

Similar Trials